Annual General Meeting of Kuros Biosciences approves all resolutions

waiting on 1882797,news,bjoern_kuper
waiting on 1882797,news,drw_holdings---c45c60af-2986-4a7f-9ee8-6d42ab2ab1c7
waiting on 1882797,news,reuters9

   Kuros Biosciences AG / Key word(s): AGMEGM
   Annual General Meeting of Kuros Biosciences approves all
   resolutions
   17.04.2024 / 14:05 CET/CEST
     ____________________________________________________________

   
   Schlieren (Zurich), Switzerland, April 17, 2024 - Kuros
   Biosciences (SIX:KURN), a leader in next generation bone graft
   technologies, held its Annual General Meeting today.

   The Annual General Meeting approved the Annual Report, the Annual
   Financial Statements, and the Consolidated Financial Statements
   for the year 2023 and took note of the Reports of the Auditors.
   Shareholders granted discharge to the Board and the Executive
   Committee, voted in favor of the proposed appropriation of the
   Annual Results, and approved the compensation for the members of
   the Board of Directors and the Executive Committee. Clemens van
   Blitterswijk was re-elected as Chairman and Joost de Bruijn as
   well as Oliver Walker were re-elected as members of the Board.
   Scott Bruder did not stand for re-election. Albert Arp and Chris
   Fair (CEO) were elected as new members of the Board of Directors.
   Clemens van Blitterswijk and Oliver Walker were re-elected as
   members of the Compensation Committee and Albert Arp was elected
   as a new member of the Compensation Committee. The law firm
   Keller AG, Zurich, was re-elected as independent Proxy.
   PricewaterhouseCoopers Ltd, Basel, were re-elected for another
   one-year term as Kuros' auditor.

   The Annual General Meeting further approved, with the required
   2/3 majority, adjustments to the articles of association.
   Adjustments included the introduction of a Capital Band and the
   increase of the Conditional Share Capital for Employees, Persons
   of Comparable Positions and Board Members.

   The Annual General Meeting took place at JED Events,
   Zürcherstrasse 39E, 8952 Schlieren (Zurich).  22'284'902 shares
   or 60.4% of a total of 36,896,008 shares were represented.

   For further information, please contact:
   Kuros Biosciences AG
   Daniel Geiger
   Chief Financial Officer
   Tel +41 44 733 47 41
   daniel.geiger@kurosbio.com LifeSci Advisors
   Sandya von der Weid
   Investors
   +41 78 680 0538
   svonderweid@lifesciadvisors.com

   About Kuros Biosciences
   Kuros Biosciences is on a mission to discover, develop and
   deliver innovative biologic fusion technologies. With locations
   in the United States, Switzerland and the Netherlands, the
   company is listed on the SIX Swiss Exchange. The company's first
   commercial product, MagnetOsTM, is a unique advanced biologic
   that has already been used across three continents in 25,000
   fusion surgeries. For more information on the company, its
   products and pipeline, visit kurosbio.com.

   Forward Looking Statements
   This media release contains certain forward-looking statements
   that involve risks and uncertainties that could cause actual
   results to be materially different from historical results or
   from any future results expressed or implied by such
   forward-looking statements. You are urged to consider statements
   that include the words "will" or "expect" or the negative of
   those words or other similar words to be uncertain and
   forward-looking. Factors that may cause actual results to differ
   materially from any future results expressed or implied by any
   forward-looking statements include scientific, business, economic
   and financial factors. Against the background of these
   uncertainties, readers should not rely on forward-looking
   statements. The Company assumes no responsibility for updating
   forward-looking statements or adapting them to future events or
   developments.

____________________________________________________________

   End of Media Release
     ____________________________________________________________

   Language:    English
   Company:     Kuros Biosciences AG
                Wagistrasse 25
                8952 Schlieren
                Switzerland
   Phone:       +41 44 733 4747
   Fax:         +41 44 733 4740
   E-mail:      info@kurosbio.com
   Internet:    www.kurosbio.com
   ISIN:        CH0325814116
   Valor:       32581411
   Listed:      SIX Swiss Exchange
   EQS News ID: 1882797

   End of News EQS News Service
     ____________________________________________________________

1882797 17.04.2024 CET/CEST